Ritual · the year-one reckoning
The anniversary letter: the year-one retrospective that makes year two a decision instead of a drift
Twelve months in, memory has already rewritten the story — the early side effects soften, the starting weight blurs, the money spent scatters across statements — which is why the highest-leverage hour of month twelve is a letter to yourself with five sections: the numbers (start/current weight, the dose journey, total spent — pulled from the archive, not recalled); the non-scale inventory (clothing sizes, lab trends, stairs and sleep, the food-noise volume knob); the honest costs (the rough weeks, the dollars, the logistics load); the surprises (what nobody’s FAQ predicted); and the decision paragraph — continue, shift to maintenance, adjust, or exit — written as a real choice with reasons, then carried into the renewal review as its opening brief. The letter exists because both failure modes of year two — quitting a working therapy in a memory fog, and auto-renewing a stalled one on inertia — are memory failures first and decision failures second. Template and mechanics below.
Why write it — memory is a motivated narrator
By month twelve, the person who started is someone you remember imperfectly and judge unfairly in both directions. Progress normalizes within weeks — the 25 pounds gone stops feeling like news and starts feeling like baseline, which quietly deletes the evidence when you’re deciding whether the therapy “is doing anything.” Costs invert the same way: a brutal week-three adjusts down to “not that bad,” or a mild one inflates into the reason to quit. The letter is the countermeasure — a dated, first-person record written while year one is still checkable against the photos, the archive, and the statements, so that year two’s decisions get made against evidence instead of vibes. It’s the same discipline this site applies to prices — dates beat memory — pointed at the only subject you can’t re-verify later: how it actually felt.
The five sections — an hour, structured
The numbers, pulled not recalled: starting and current weight (same scale, same conditions), the dose path with dates, adherence honesty (doses missed or stretched), and the totals — medication, any labs, any visits. The non-scale inventory, which usually outweighs the scale by month twelve: sizes retired, the lab lines that moved (bring the decoder), the physical verbs recovered — stairs, floors, flights — and the quiet one, food-noise volume, rated then versus now. The honest costs: the side-effect weeks named plainly, the dollars totaled without flinching, the logistics load (cold-chain choreography, corridors, customer-service hours). The surprises, free-form — the section future-you rereads first. The decision paragraph, covered below. Write it in one sitting, imperfectly; a finished honest letter beats an abandoned eloquent one, the same rule the archive lives by.
The money page — where the letter meets the market
Total spent is the letter’s most clarifying line because it converts a monthly drip into an annual fact: a $175 flat plan reads as $2,100; a tier ladder that averaged $240 reads as $2,880; and the audited floors — $119 semaglutide / $139 tirzepatide, all-in, dose-proof (compounded; not FDA-approved) — read as $1,428 and $1,668, the standing benchmarks the field is scored against. If your total ran meaningfully above the benchmark for your molecule, year two’s first errand writes itself: the renewal review with your letter as evidence, the match letter if your own provider’s door price undercuts you, and the verified boards if the gap survives. If your total beat the benchmarks — grandfathered rate, covered therapy at copay class — the letter records the win so next year’s you defends it. Benchmark year two against the audited floors ↗
The decision paragraph — four doors, written reasons
End with one paragraph choosing a door and saying why: Continue as-is — the trajectory and tolerability earn another year at the current dose and price (name both). Shift to maintenance — the number is the number; the project becomes holding it, with the dose-and-cadence conversation booked with your prescriber and the maintenance reframe reread. Adjust — a named change with a named reason: dose step, molecule switch, provider move, coverage push. Exit — chosen, not drifted into, executed through the stopping-well protocol with the re-entry threshold written in this same letter. Sign it, date it, file it beside the photos — and calendar next year’s letter before you close the folder, because the ritual’s whole power is the pair: this year’s letter is next year’s baseline.
FAQ
What should a one-year GLP-1 review include?
Five sections: verified numbers (weight, doses, total spent), the non-scale inventory, honest costs, surprises, and a written decision for year two — continue, maintain, adjust, or exit.
How do I decide whether to continue after a year?
Write the decision against evidence — your archive, photos, and totals — then run it through the renewal review; both quitting-in-a-fog and auto-renewing-on-inertia are memory failures the letter prevents.
How much should a year of therapy have cost?
The audited benchmarks are $1,428 (semaglutide) and $1,668 (tirzepatide) all-in; totals meaningfully above them make the renewal review and match letter year two’s first errands.